We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Studies of Suppressor Gene Advance Understanding of Metastasis

By LabMedica International staff writers
Posted on 17 Jan 2016
A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer and these findings may lay the foundation for new colorectal cancer treatments.

Cancer deaths attributed to colorectal cancer are mainly due to tumor recurrence and metastasis to other organs and excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the USA. More...
It is estimated that the lifetime risk of developing colorectal cancer is about 1 in 20.

Scientists at the University of Missouri (Columbia, MO, USA) used cancer cell models, mouse models and human biopsy samples and by using different molecular methods, the team found that the Sprouty2 (SPRY2) gene functions differently in colorectal cancer (CRC) than in other types of cancers. Sprouty (SPRY) is an intracellular regulator of receptor tyrosine kinase signaling involved in growth, differentiation and tumorigenesis. Four family members of SPRY (SPRY1–4) have been identified. SPRY2 appears to be ubiquitously expressed, whereas other family members show organ and tissue specificity.

Among the various techniques used, 3′UTR reporter assays were performed and the luminescence was measured by a luminometer (Turner Biosystems Inc.; Sunnyvale, CA, USA) confocal microscopy using a Leica TCS SP8 confocal laser scanning microscope (Leica Microsystems Inc.; Buffalo Grove, IL, USA) was performed; and formalin-fixed, paraffin-embedded human colorectal cancer (CRC) tissue microarray (Biomax; Rockville, MD, USA) was utilized for V-Akt Murine Thymoma Viral Oncogene Homolog 2(AKT2) and E-cadherin (CDH1) immunostaining.

The team found that in colorectal cancer, SPRY2 may increase the metastatic ability of cancer cells instead of suppress it. SPRY1 and SPRY2 messenger ribonucleic acid (mRNA) transcripts were significantly upregulated in human CRC. Suppression of SPRY2 repressed AKT2 and epithelial-mesenchymal transition inducing transcription factors and significantly increased E-cadherin expression. Concurrent downregulation of SPRY1 and SPRY2 also increased E-cadherin and suppressed mesenchymal markers in colon cancer cells. By confocal microscopy, they demonstrated redistribution of E-cadherin to plasma membrane in colon cancer cells transfected with miR-194.

Sharad Khare, PhD, an associate professor and senior author of the study said, “The gene known as Sprouty2 has previously been shown to protect against metastasis, or the spreading of cancer to other parts of the body, in breast, prostate and liver cancer. However, our recent molecular studies found that this gene may actually help promote metastasis instead of suppress it. This finding is a very significant step in our understanding of metastasis in colorectal cancer, but it's important to note that we believe this phenomenon may occur in only a subset of colorectal cancer patients.” The study was published originally in advance of print, online on October 5, 2015, in the journal Oncogene.

Related Links:

University of Missouri
Turner Biosystems Inc. 
Leica Microsystems Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.